Clinical Trials Logo

Clinical Trial Summary

Lung transplantation is used to treat patients with lung damage when there is no other treatment option. Patients require close monitoring following their transplant, with hospital check-ups every 3-4 months usually lasting all day. Although check-ups often result in no change to patient management they are essential as patients have better outcomes if complications are detected quickly. The aim is to explore whether remote monitoring via an app (patientMpower) ± questionnaire (specifically designed to assess post-transplant patients' health), linked to a device to measure lung function, could replace some check-ups for lung transplant patients. Patients will be randomised to receive either normal care or remote monitoring (i.e. their symptoms will be evaluated using home spirometry combined with a questionnaire). 100 lung transplant recipients will be enrolled with 50 patients being assigned to either group. Health outcomes and costs of care between the two groups will be compared


Clinical Trial Description

100 lung transplant patients are expected to be recruited. Consent will be taken by the research team. Following admission they will be randomised to the interventional or control arms. The control arm will consist of follow-up according to unit policy, in the majority of cases this will be every 3 months. The only change is that when they come to follow up the patients will be asked to fill in the same interventional questionnaire (designed to assess post-transplant lung health) that the interventional arm are completing. However, they will be seen regardless of what this questionnaire reports. This will act as validation for the questionnaire. The interventional arm will replace the 3 monthly visits with a questionnaire which the patient will be asked to complete and then this will be returned to the unit. The patient can fill this in via the app, or on paper and return the questionnaire via email or post. The duty clinician will then review the questionnaire and combine this with the home spirometry data which the patient is already completing to see if the patient needs to be seen. In the majority of cases, its expected that the patient will not need to be seen as the clinic visits in lung transplant are mainly monitored and the vast majority of the patients are seen every 3-4 months. Regardless of the outcome, the participant will receive a phone call from the transplant nurse within 48 hours of the appointment to discuss the results of the blood test and confirm that they are okay. In addition to the questionnaire to assess lung health, all participants will be asked to complete other respiratory/sleep questionnaires such as Saint George's Respiratory (SGRQ), Morningness-eveningness (MEQ-SA) and the Pittsburgh Sleep Quality Index (PSQI). This will investigate whether more complex questionnaires are needed to see if patients require clinical follow-up. Study duration is predicted to be 6 months per participant. During the whole study, volunteers will be asked to wear an activity tracker such as Fitbit. Using the device's application programming interface (API) investigators will be able to remotely access data concerning heart rate, accelerometry and sleep duration, including stages of sleep. This will be accessed as required anticipated to be once per week, followed by phone calls to patients should the data be missing. In addition, their clinical record will also be accessed to obtain clinical data for instance if a sleep study has been performed. Patients will be asked to perform daily home spirometry using a Bluetooth enabled spirometer. It is currently being used in the Manchester lung transplant program. If patients have not submitted a reading for one week then they will be contacted by the study team to offer assistance. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05916495
Study type Interventional
Source University of Manchester
Contact Rebecca Borton
Phone +442033224121
Email researchoffice@patientmpower.com
Status Recruiting
Phase N/A
Start date September 29, 2023
Completion date December 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05526950 - Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb) N/A
Enrolling by invitation NCT05950724 - RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant Early Phase 1
Active, not recruiting NCT05505422 - Routine Versus Selective Intraoperative ECMO in Lung Transplant N/A
Recruiting NCT05081141 - HHV8 and Solid Organ Transplantation
Enrolling by invitation NCT04522388 - Examining the Effect of Nutritional Supplementation on Skeletal Muscle Mass in Patients Awaiting Lung Transplant N/A
Completed NCT04165161 - Performance Diagnosis of a Patent Foramen Ovale During Lung Transplantation Using Transesophageal Echocardiography N/A
Recruiting NCT05050955 - AlloSure Lung Assessment and Metagenomics Outcomes Study
Withdrawn NCT03258801 - Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis
Completed NCT04892719 - 4DX Functional Lung Imaging in the Diagnosis of Chronic Lung Allograft Dysfunction After Lung Transplantation N/A
Completed NCT03221764 - Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients Phase 2
Active, not recruiting NCT04975607 - Live Music Therapy to Reduce Anxiety, Pain and Improve Sleep in Post-Operative Lung Transplant Patients: A Pilot Study N/A
Completed NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT03367221 - Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist N/A
Recruiting NCT03276403 - Primary Graft Dysfunction Score in Lung Transplantation N/A
Active, not recruiting NCT03656926 - Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Phase 3
Completed NCT05242289 - Cytokine Adsorption in Lung Transplantation N/A
Recruiting NCT04837339 - Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation N/A
Not yet recruiting NCT04377139 - Management of Cytomegalovirus (CMV) Infection in Lung Transplant Recipients (LTR)
Not yet recruiting NCT06399302 - Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
Terminated NCT03562416 - Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects Phase 2